Canada's Bausch Health Q2 results beat estimates; raises 2026 outlook

Bausch Health Companies

29/07/2026 21:24

Overview
Canada pharma maker's Q2 revenue rose 13% yr/yr, beating analyst expectations
Adjusted EPS for Q2 increased 40% yr/yr and beat analyst expectations
Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook
Bausch Health raises full-year 2026 revenue guidance to $10.79-$11.04 bln
Company expects 2026 adjusted EBITDA of $4.05-$4.18 bln, up 8%-11% vs prior yr
Company says uncertainty around tariffs may affect results in 2026

Result Drivers
SALIX SEGMENT GROWTH - Revenue in the Salix segment rose 21% yr/yr, led by 26% growth in Xifaxan sales
SOLTA MEDICAL ACQUISITION - Solta Medical revenue rose 38%, aided by acquisition of a full service distributor in China
INTERNATIONAL SEGMENT EXECUTION - International segment revenue grew 10%, with strong execution in LATAM and EMEA offsetting softer results in Canada

Company press release: ID:nPn7tt90ga

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$2.85 bln
$2.66 bln (3 Analysts)
Q2 Adjusted EPS
Beat
$1.26
$1.04 (3 Analysts)
Q2 EPS
 
$0.68
 
Q2 Net Income
 
$260 mln
 
Q2 Adjusted EBITDA
Beat
$1.08 bln
$937 mln (2 Analysts)
Q2 Operating Income
 
$740 mln
 
Q2 Pretax Profit
 
$348 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 1 three months ago

Reuters Recommended Reads
July 29 - Bausch + Lomb Q2 revenue beats on surgical segment growth; lifts outlook
July 29 - Teva Pharm profit misses estimates, seeks US tariff details
July 28 - GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)